TENDENCY OF INCIDENCE WITH EPILEPSY IN KAZAKHSTAN
DOI:
https://doi.org/10.54890/.v5i5-6.434Abstract
According to the WHO, epilepsy accounts for approximately 1% of the world’s total disease burden, and is fourth on the list of neuropsychiatric disorders, following depression, alcoholism, and cerebrovascular disease, with similar impact to the burden of breast and lung cancer. It affects over 70 million people worldwide and it's characterized by a lasting predisposition to generate spontaneous epileptic seizures and has numerous neurobiological, cognitive, and psychosocial consequences.
Aim. To study the trends of epilepsy incidence in Kazakhstan.
Material and methods: The research material was compiled summary reporting form number 12 of Ministry of Health of the Republic of Kazakhstan on new cases of epilepsy (ICD-10 – G40), established for the first time. A retrospective study was used as the main method for studying the incidence of epilepsy. According to generally accepted methods of biomedical statistics, extensive, intensive and equalized indicators of the incidence of epilepsy were calculated.
Results. For 2009-2018 78,429 new cases of epilepsy were registered in the republic, of which were in children – 47.6%, teenagers – 7.5% and adults –44.8%. The average annual incidence rate of epilepsy in the entire population of Kazakhstan was 45.6±3.00/0000 (95% CI=39.7-51.40/0000), and for population groups having been studied was: in children – 83.2±4.00/0000 (95%CI=75.4-91.00/0000), among teenagers – 84.6±6.50/0000 (95% CI=71.9-97.30/0000) and the adult population 29.3±2.60/0000 (95% CI=24.3-34.30/0000). The difference in incidence between groups was statistically significant. Disease tended to increase in all age groups: in children (Т=+5.7%), in adolescents (T=+9.8%) and in the adult population (Т=+9.8%).
Conclusion. According to the dynamics, epilepsy incidence in Kazakhstan has a increased tendency. The results obtained are recommended to be taken into account by health authorities when making managerial decisions.
Keywords:
epilepsy, morbidity, age characteristics, epidemiology, trends, Kazakhstan.References
1. Ali A. Global Health: Epilepsy. Semin Neurol. 2018;38(2):191-99. doi:10.1055/s-0038-1646947.
2. Atlas: Epilepsy care in the world. Geneva, Switzerland: World Health Organization; 2005. World Health Organization.
3. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–82.
4. Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689-701.doi:10.1016/S0140-6736(18)32596-0.
5. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49(9):1491–503.
6. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ 2010;88(4):260–6.
7. Neligan A, Sander JW. The treatment gap in epilepsy. A global perspective. Epileptology. 2013;1:28–30.
8. Epilepsy: a public health imperative. Summary. Geneva: World Health Organization; 2019 (WHO/MSD/MER/19.2). Licence: CC BY-NC-SA 3.0 IGO.
9. Guerreiro CA. Epilepsy: Is there hope? Indian J Med Res. 2016;144(5):657-660. doi:10.4103/ijmr.IJMR_1051_16.
10. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676–85.
11. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM). ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512–21.